|Bid||176.70 x 1000|
|Ask||176.61 x 1200|
|Day's Range||174.07 - 177.15|
|52 Week Range||155.72 - 186.69|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||26.45|
|Forward Dividend & Yield||4.52 (2.56%)|
|Ex-Dividend Date||May 23, 2022|
|1y Target Est||N/A|
Selling the call option generates an income of 1.7% in just under one month, equaling around 26.7% annualized.
Johnson & Johnson (NYSE: JNJ) is ready to cough up an hourly rate of $2,465 in a bid to add Hogan Lovells partner Neal Katyal to its legal team for the talc liability case. The controversial bankruptcy case tries to free JNJ from potentially billions in liabilities over its talc products claiming to cause cancer. The U.S. government is objecting, citing his hourly rate as a possible new legal industry high. Related: Johnson & Johnson's Baby Talc Litigation, Faces Fresh Claims It Hid Evidence: Bl
Pharma stocks Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) have gained 23% and 5%, respectively, year to date. Merck had five blockbuster products in 2021, including the top-selling cancer drug in the world, Keytruda.